Liquidia Corporation, a biopharmaceutical company focused on products for pulmonary hypertension and other uses of its PRINT® Technology, announced that Michael Kaseta, COO and CFO, will be speaking at the BofA Securities Health Care Conference 2024 in Las Vegas, Nevada on May 14, 2024. The fireside chat will begin at 5:00 p.m. PT and a webcast will be available on Liquidia’s website for investors and interested parties.
Liquidia Corporation operates through its subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. They are also working on L606, a liposomal formulation of treprostinil for use in North America. Liquidia PAH focuses on commercializing pharmaceutical products for pulmonary diseases.
The company is dedicated to providing innovative solutions to patients with respiratory diseases through its proprietary PRINT® technology platform which allows the delivery of drug directly into the lungs at high efficiency levels while minimizing systemic side effects. Additionally, Liquidia is committed to improving patient outcomes by developing new treatments that address unmet medical needs in the field of pulmonary hypertension and other respiratory diseases.
